The Influence of Baseline Diastolic Blood Pressure on the Effects of Intensive Blood Pressure Lowering on Cardiovascular Outcomes and All-Cause Mortality in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To examine whether low baseline diastolic blood pressure (DBP) modifies the effects of intensive systolic blood pressure (SBP) lowering on cardiovascular outcomes in type 2 diabetes mellitus (T2DM). RESEARCH DESIGN AND METHODS: The Action to Control Cardiovascular Risk in Diabetes Blood Pressure trial (ACCORD BP), a two-by-two factorial randomized controlled trial, examined effects of SBP (<120 vs. <140 mmHg) and glycemic (HbA1c <6% vs. 7.0–7.9% [<42 vs. 53–63 mmol/mol]) control on cardiovascular events in T2DM (N = 4,731). We examined whether effects of SBP control on cardiovascular composite were modified by baseline DBP and glycemic control. RESULTS: Intensive SBP lowering decreased the risk of the cardiovascular composite (hazard ratio [HR] 0.76 [95% CI 0.59–0.98]) in the standard glycemic arm but not in the intensive glycemic arm (HR 1.06 [95% CI 0.81–1.40]). Spline regression models relating the effects of the intervention on the cardiovascular composite across the range of baseline DBP did not show evidence of effect modification by low baseline DBP for the cardiovascular composite in the standard or intensive glycemic arms. The relation between the effect of the intensive SBP intervention and baseline DBP was similar between glycemic arms for the cardiovascular composite three-way interaction (P = 0.83). CONCLUSIONS: In persons with T2DM, intensive SBP lowering decreased the risk of cardiovascular composite end point irrespective of baseline DBP in the setting of standard glycemic control. Hence, low baseline DBP should not be an impediment to intensive SBP lowering in patients with T2DM treated with guideline-recommended standard glycemic control.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“However, in ACCORD BP, it was found that intensive blood pressure lowering decreased the risk of cardiovascular events irrespective of baseline diastolic blood pressure in patients who also received standard glycemic control (44).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [44]
The cited source says what the claim attributes to it.
In the citing paper
“However, ACCORD BP demonstrated that intensive blood pressure lowering decreased the risk of cardiovascular events irrespective of baseline diastolic blood pressure in individuals who also received standard glycemic management (51).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [51]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2018 ESC/ESH Guidelines for the management of arterial hypertension
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy339 · Cited by 10,286
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000065 · Cited by 7,391
Self-citationProportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885 · cited 1×
“Analyses of scaled Schoenfeld residuals (21) indicated no evidence of nonproportional hazards.”
BackgroundEffects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837 · cited 2×
“Statistical analyses and preparation of this manuscript were supported by grants from the National Heart, Lung, and Blood Institute (NHLBI) (R21-HL-145494), National Institute of Diabetes and Digestive and Kidney Diseases (R01-DK-091437), and the University of Utah Study Design and Biostatistics Center (funded in part…”
MethodMicrovascular and Macrovascular Complications of Diabetes
Fowler, M. J. (2008) · Clinical Diabetes · doi:10.2337/diaclin.26.2.77 · Cited by 1,954
The J-Curve Phenomenon in Hypertension
Kang, Y.-Y., & Wang, J.-G. (2016) · Pulse · doi:10.1159/000446922 · Cited by 1,530
Excess Mortality among Persons with Type 2 Diabetes
Tancredi, M., Rosengren, A., Svensson, A.-M., Kosiborod, M., Pivodic, A., Gudbjörnsdottir, S., Wedel, H., Clements, M., Dahlqvist, S., & Lind, M. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504347 · Cited by 996
Cited by
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
2024 ESC Guidelines for the management of elevated blood pressure and hypertension
McEvoy, J. W., McCarthy, C. P., Bruno, R. M., Brouwers, S., Canavan, M. D., Ceconi, C., Christodorescu, R. M., Daskalopoulou, S. S., Ferro, C. J., Gerdts, E., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae178 · Cited by 2,298
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s010 · Cited by 869
“However, in ACCORD BP, it was found that intensive blood pressure lowering decreased the risk of cardiovascular events irrespective of baseline diastolic blood pressure in patients who also received standard glycemic control (43).”
BackgroundJoseph, J. J., Deedwania, P., Acharya, T., Aguilar, D., Bhatt, D. L., Chyun, D. A., Di Palo, K. E., Golden, S. H., Sperling, L. S., & on behalf of the American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Arteriosclerosis, T. A. V. B. C. O. C. C. A. C. O. H. (2022) · Circulation · doi:10.1161/cir.0000000000001040 · Cited by 660
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Das, S. R., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s010 · Cited by 465
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Das, S. R., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s010 · Cited by 438
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Das, S. R., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s010 · Cited by 486
Arvanitis, M., Qi, G., Bhatt, D. L., Post, W. S., Chatterjee, N., Battle, A. J., & McEvoy, J. W. (2020) · Circulation · doi:10.1161/circulationaha.120.049819 · Cited by 122
Guan, H., Tian, J., Wang, Y., Niu, P., Zhang, Y., Zhang, Y., Fang, X., Miao, R., Yin, R., & Tong, X. (2024) · European journal of medical research · doi:10.1186/s40001-024-01739-1 · Cited by 63
Wu, Z., Yu, S., Zhang, H., Guo, Z., Zheng, Y., Xu, Z., Li, Z., Liu, X., Li, X., Chen, S., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01696-1 · Cited by 25
“Intensive blood pressure control decreased the risk of cardiovascular outcomes in diabetic population [43, 44].”
BackgroundThe diastolic blood pressure J-curve revisited: An update
Filippone, E. J., Foy, A., & Naccarelli, G. V. (2021) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2021.100065 · Cited by 30
“Ilkun et al. assessed the effect modification of baseline DBP in ACCORD-BP on the primary outcome and the interaction with randomized glycemic control [39].”
BackgroundShihab, S., Boucher, R. E., Abraham, N., Wei, G., & Beddhu, S. (2022) · Hypertension · doi:10.1161/hypertensionaha.121.18172 · Cited by 18
Self-citationWeir, M. R. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15764 · Cited by 18
“28 These observations would argue that a low DBP is not necessarily a contraindication and support the idea of more intensive SBP management.”
Huang, Q., Nan, W., He, B., Xing, Z., & Peng, Z. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02622-x · Cited by 14
Kianmehr, H., Guo, J. S., Lin, Y., Luo, J., Cushman, W. C., Shi, L., Fonseca, V. A., & Shao, H. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108287 · Cited by 12
Zhou, C., Yi, Q., Luo, Y., Wei, H., Ge, H., Liu, H., Li, X., Zhang, J., Pan, P., Yi, M., et al. (2003) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002666 · Cited by 11
Lauder, L., Rahimi, K., Böhm, M., & Mahfoud, F. (2025) · Hypertension · doi:10.1161/hypertensionaha.125.25466 · Cited by 9
Wu, J., Zhao, X., Chen, H., & Zhu, S. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108352 · Cited by 9
Sarwal, A., Boucher, R. E., Hartsell, S. E., Wei, G., Shen, J., Chertow, G. M., Whelton, P. K., Cheung, A. K., McEvoy, J. W., Greene, T., et al. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000539 · Cited by 9
Self-citationTreatment and Control of Hypertension Among Adults With Chronic Kidney Disease, 2011 to 2019
Martinez, J. D., Thomas, I., Montez‐Rath, M. E., Pao, A. C., Fung, E., Charu, V., Sim, J. J., An, J., Odden, M. C., & Tamura, M. K. (2023) · Hypertension · doi:10.1161/hypertensionaha.123.21523 · Cited by 8
“…not warranted as there was no evidence that intensive BP treatment increased adverse events in trial participants with low baseline diastolic BP. 23,24 Whether these results can be generalized to the broader population remains a point of controversy, and current guidelines still emphasize the…”
BackgroundLi, C., Chen, K., Shi, G., Shi, R., Wu, Z., Yuan, X., Watson, V., Jiang, Z., Mai, H., Yang, T., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02407-z · Cited by 8
“This was also supported by some early studies [1, 18, 27].”
ResultAnother Nail in the Coffin of Causality for the Diastolic Blood Pressure J Curve
Birrane, J. P., Foschi, M., Sacco, S., & McEvoy, J. W. (2022) · Hypertension · doi:10.1161/hypertensionaha.122.18997 · Cited by 7
Liew, C. H., & McEvoy, J. W. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa627 · Cited by 5
Yang, R., Huang, R., Zhang, L., Li, D., Luo, J., & Cai, J. (2023) · Hypertension · doi:10.1161/hypertensionaha.123.21892 · Cited by 4
“23 However, the target SBP was 120 mm Hg in both SPRINT The association between baseline diastolic blood pressure expressed as a continuous variable and the effects of intensive blood pressure lowering was evaluated using restricted cubic splines.”
MethodMousavi, A., Shojaei, S., Abhari, A. P., Mirhosseini, S. A., Ebrahimi, R., Rajabi, E., Farooqi, M. A., Azizpour, A., Moghadam, S. A., Kuno, T., et al. (2025) · American Journal of Hypertension · doi:10.1093/ajh/hpaf140 · Cited by 4
Coca, A., Sanchez, R., SALAZAR, D. I. M. D., Peñaherrera, E., Alcocer, L., Barbosa, E., Grassi, G. M., López-Jaramillo, P. A., Lurbe, E., Parra-Carrillo, J. Z., et al. (2026) · Journal of Hypertension · doi:10.1097/hjh.0000000000004290 · Cited by 4
Self-citationDiastolic Blood Pressure and the J-Curve—Causal Effect or Confounding?
Hartsell, S. E., & Beddhu, S. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.30031 · Cited by 3
Self-citationSmith, C., Berry, J. D., Scherzer, R., de Lemos, J. A., Nambi, V., Ballantyne, C. M., Kravitz, R. L., Killeen, A. A., Ix, J. H., Shlipak, M. G., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032493 · Cited by 3
“• Among individuals with hypertension and low DBP, the presence of elevated hs-cTnT levels identifies a high-risk group that may account for the J-curve relationship between DBP and cardiovascular disease risk.”
BackgroundInfluentialHypertension and Type 2 Diabetes
Redón, J., & Martínez, F. (2022) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-13009-0_3 · Cited by 2
Diastolic Blood Pressure Does Not Influence Cardiovascular Outcomes in Type 2 Diabetes; or Does It?
Sarafidis, P. A., & Bakris, G. L. (2020) · Diabetes Care · doi:10.2337/dci20-0019 · Cited by 2
“(19) present a post hoc analysis of 4,731 ACCORD BP patients, examining whether baseline DBP modifies the effects of intensive SBP control”
BackgroundLi, X., Yi, Q., Luo, Y., Wei, H., Ge, H., Liu, H., Zhang, J., Li, X., Xie, X., Pan, P., et al. (2024) · Respiration · doi:10.1159/000541367 · Cited by 5
McEvoy, J. W., McCarthy, C. P., Brouwers, S., & Others, A. (2025) · HYPERTENSION · doi:10.22141/2224-1485.17.4.2024.372 · Cited by 2
Lin, R.-T., Gao, J., Yang, Y.-C., Chen, X.-W., Gu, Z.-J., Tian, L.-G., Chen, Z.-L., & Zhang, L. (2025) · Journal of Hypertension · doi:10.1097/hjh.0000000000004037 · Cited by 1
Liew, C. H., & McEvoy, J. W. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91391-1.00031-5 · Cited by 3
Xi, X., Yin, G., Wang, X., & Li, X. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-2439 · Cited by 1
Blood Pressure Thresholds for Initiation of Drug Treatment: Blood Pressure Targets in Diabetes
Dhaybi, O. A., & Bakris, G. L. (2022) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-13009-0_23 · Cited by 1
Predicting hypertension in type 2 diabetes mellitus: Insights from a nomogram model
Liu, J., Zhang, N., & Liu, T. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i7.107501 · Cited by 4
Blood Pressure Limbo—How Low Can You Go?
Matar, A., & McEvoy, J. W. (2021) · Diabetes Care · doi:10.2337/dci21-0017
“Therefore, the higher risk for CVD may not be related directly to lower DBP in these patients; instead, it might reflect the fact that adults with low DBP are typically older and have other comorbidities like underlying vascular stiffness and heart failure (this is supported by the lack of DBP J curve in the randomize…”
BackgroundThompson, B., & McEvoy, J. W. (2021) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2021.2013814 · Cited by 1
Systolische Blutdrucksenkung auch bei niedrigem diastolischem Wert wichtig
(2020) · Diabetologie und Stoffwechsel · doi:10.1055/a-1265-1846
Siński, M., Berka, P., Lewandowski, J., Sobieraj, P., Piechocki, K., Paleczny, B., & Siennicka, A. E. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11247454
Miloslavsky, D. К., & Koval, S. M. (2024) · Shidnoevropejskij zurnal vnutrisnoi ta simejnoi medicini · doi:10.15407/internalmed2024.01.120
Cardiovascular Disease and Risk Management
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch17
Li, C., Chen, K., Shi, G., Shi, R., Wu, Z., Yuan, X., Watson, V., Jiang, Z., Mai, H., Yang, T., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20099677
Metadata
- Authors
- Ilkun, O. L., Greene, T., Cheung, A. K., Whelton, P. K., Wei, G., Boucher, R. E., Ambrosius, W., Chertow, G. M., & Beddhu, S.
- Affiliations
- University of Utah (US)
- Tulane University (US)
- Wake Forest University Health Sciences (US)
- Stanford Medicine (US)
- Corresponding author
- Beddhu, Srinivasan
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-05-04
- Volume
- 43
- Issue
- 8
- Pages
- 1878-1884
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC7372050
- OpenAlex
- W3021187935
- Cited by
- 46
- References
- 31
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 8 · 2023: 7 · 2022: 13 · 2021: 5 · 2020: 4
- FWCI
- 4.48
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R21-HL-145494)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01-DK-091437)
- U.S. Public Health Service (UL1-RR-025764, C06-RR-11234)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, diastolic blood pressure, intensive blood pressure lowering, systolic blood pressure, cardiovascular outcomes, all-cause mortality, glycemic control, HbA1c, effect modification, baseline blood pressure
- MeSH terms
- Aged, Antihypertensive Agents, Blood Glucose, Blood Pressure, Blood Pressure Determination, Cause of Death, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Diastole, Female, Humans, Hypertension, Male, Middle Aged, Mortality, Systole
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.